Parkinson's disease: Focus on management alternatives

American Journal of Managed Care

Volumn 6, Issue 1, 2000, Pages 93-113

  Young, Linda R ^a,b   Justice, Lori N ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANESTHETIC AGENT; ANTACID AGENT; ANTIBIOTIC AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; BIPERIDEN; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPHENHYDRAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HYDANTOIN; LEVODOPA; MACROLIDE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; PERGOLIDE; PERGOLIDE MESILATE; PRAMIPEXOLE; PROCYCLIDINE; RITONAVIR; ROPINIROLE; SELEGILINE; TOLCAPONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL; UNINDEXED DRUG;

CONTINUING EDUCATION; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; NEUROLOGIC DISEASE; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ACTIVITIES OF DAILY LIVING; ANTIPARKINSON AGENTS; COST OF ILLNESS; DISEASE MANAGEMENT; EDUCATION, PHARMACY, CONTINUING; HUMANS; MONITORING, PHYSIOLOGIC; PARKINSON DISEASE; PATIENT EDUCATION;

EID: 0033977582     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Nelson MV, Berchou RC, LeWitt PA. Parkinson's disease. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: A Pathophysiologic Approach, 4th ed. Stamford, CT: Appleton & Lange; 1999:1001-1013.
2. Flaherty JF, Gidal BE. Parkinson's disease. In: Young LY, Koda-Kimble MA. Applied Therapeutics: The Clinical Use of Drugs, 6th ed. Vancouver, WA: Applied Therapeutics, Inc; 1995:51-1-51-16.
3. Colcher A, Simuni T. Parkinson's disease and parkinsonian syndromes. Med Clin North Am 1999;83:327-347.
4. Shimomura SK, Fujimoto D. Parkinsonism. In: Herfindal ET, Gourley DR, eds. Textbook of Therapeutics: Drug and Disease Management, 6th ed. Baltimore, MD: Williams & Wilkins; 1996:1035-1045.
5. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996;14:317-335.
6. Adler CH. Parkinson's disease and parkinsonian syndromes: Differential diagnosis of Parkinson's disease. Med Clin North Am 1999;83:349-367.
7. Jankovic J. The extrapyramidal disorders. In: Bennett JC, Plum F. Cecil Textbook of Medicine, 20th ed. Philadelphia, PA: WB Saunders Co; 1996:2128-2137.
8. Fahn S. Parkinsonism. In: Rowland LP, ed. Merritt's Textbook of Neurology, 9th ed. Baltimore, MD: Williams & Wilkins; 1995:713-730.
9. Barbosa ER, Papaterra Limongi JC, Cummings JL. Neuropsychiatry of the basal ganglia: Parkinson's disease. Psychiatr Clin North Am 1997;20:769-790.
10. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, Inc; 1996:503-519.
11. Beal MF, Fink JS, Martin JB. Parkinson's disease and other extrapyramidal disorders. In: Isselbach KJ, Martin JB, Braunwald E, Fauci AS, Wilson JD, Kasper DL, eds. Harrison's Principles of Internal Medicine, 13th ed. New York, NY: McGraw-Hill, Inc; 1998:2275-2280.
12. Gomez-Tortosa E, Ingraham AO, Irizarry MC, Hyman BT. Geriatric bioscience: Dementia with Lewy bodies. J Am Geriatr Soc 1998;46:1449-1458.
13. Diederich NJ, Goetz CG. Iatrogenic disorders: Drug-induced movement disorders. Neurol Clin 1998;16:125-139.
14. Koller WC, Montgomery EB. Issues in the early diagnosis of Parkinson's disease. Neurology July 1997;49:PS010-PS025.
15. Hoèhn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967 May;17:427-442.
16. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: Treatment guidelines. Neurology 1998;50(suppl 3):S1-S55.
17. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997;45:844-849.
18. Arle JE, Alterman RL. Surgical options in Parkinson's disease. Med Clin North Am 1999;83:483-498.
19. Kastrup EK, ed. Drug Facts and Comparisons. St. Louis, MO: Wolters Kluwer; 1999:289b-290w.
20. United States Pharmacopeial Convention. Drug Information for the Health Care Professional, vol 1. 19th ed. Taunton, MA: World Color Book Services; 1999: 58-61, 636-639, 765-769, 1848-1852, 2284-2286, 2365-2368, 2525-2528, 2560-2562, 2833-2836.
21. Wasielewski PG, Koller WC. Quality of life and Parkinson's disease: The CR first study. J Neurology 1998;245(suppl 1):S28-S30.
22. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD. A 5-year randomized multicenter study. Neurology 1999;53:1012-1019.
23. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD. Neurology 1999;53:573-579.
24. Koller WC, Rueda MG. Mechanism of action of dopaminergic agents in Parkinson's disease. Neurology 1998;50(suppl 6):S11-S14.
25. Factor SA. Parkinson's disease and parkinsonian syndromes. Med Clin North Am 1999;83:415-443.
26. Ogawa N. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease. Neurology 1998;51(suppl 2):S13-S20.
27. Poewe W. Adjuncts to levodopa therapy: Dopamine agonists: Neurology 1998;50(suppl 3):S23-S26.
28. Mirapex [package insert]. Kalamazoo, MI: Pharmacia & Upjohn Co; June 1997.
29. Requip [package insert]. Philadelphia, PA: Smith Kline Beecham Pharmaceuticals; September 1997.
30. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA 1997;278:125-130.
31. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997;49:724-728.
32. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065.
33. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999;66:436-441.
34. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997;49:162-168.
35. Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908-1910.
36. Mirapex Dear Health Care Professional letter. Available at: http://www.fda.gov/medwatch/safety/1999/mirape.htm. Accessed November 14, 1999.
37. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997;49:393-399.
38. Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson disease: A 12-month experience. Ropinirole Study Group. Arch Neurol 1998;55:1211-1216.
39. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:1057-1062.
40. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology 1999;53:364-370.
41. Schwab RS, England AC Jr, Poskanzer DC, Young RR. Amantadine in the treatment of Parkinson's disease. JAMA 1969;208:1168-1170.
42. Timberlake WH, Vance MA. Four-year treatment of patients with parkinsonism using amantadine alone or with levodopa. Ann Neurol 1978;3:119-128.
43. Metman LV, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
44. Pezzoli G, Martignoni E, Pacchetti C, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 1995;45(suppl 3):S22-S27.
45. Tasmar [package insert]. Nutley, NJ: Roche Laboratories, lnc; November 1998.
46. Adler CH, Singer C, O'Brien C, et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch Neurol 1998;55:1089-1095.
47. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997;48:81-87.
48. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997;49:665-671.
49. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyl-transferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997;63:421-428.
50. Food and Drug Administration. New warnings for Parkinson's drug, Tasmar. Rockville, MD: National Press Office; November 16, 1998. Talk Paper T98-81.
51. The NDA Pipeline-1998 [book on CD-ROM]. Supplemental edition. Chevy Chase, MD: F-D-C Reports, Inc; 1999.
52. Rinne UK, Larson JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998;51:1309-1314.
53. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
54. Comtan [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 1999.
55. Bodagh IYO, Robertson DRC. A risk-benefit assessment of drugs used in the management of Parkinson's disease. Drug Safety 1994;11:94-103.
56. Bryson HM, Milne RJ, Chrisp P. Selegiline. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease. Pharmacoeconomics 1992;2:118-136.
57. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Neurology 1998;51:520-525.
58. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1607.
59. Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson's disease research group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: Further results of randomised trial and confidential inquiry. BMJ 1998;316:1191-1196.
60. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report. BMJ 1993;307:469-472.
61. Olanow CW, Myllyla VV, Sotaniemi KA. Effect of selegiline on mortality in patients with Parkinson's disease. A meta analysis. Neurology 1998;51:825-830.
62. Lang AE, Lozano AM. Parkinson's disease, part II. N Engl J Med 1998;339:1130-1143.
63. AmeriSource average wholesale price [microfiche]. Malvern, PA: AmeriSource, Inc. August 16, 1999.
64. Kurth MC, Tetrud JW, Irwin I, Lyness WH, Langston JW. Oral levodopa/carbidopa solution versus tablets in Parkinson's patients with severe fluctuations: A pilot study. Neurology 1993;43:1036-1039.
65. Unified Parkinson's Disease Rating Scale. Available at: http://www.wemove.org/par_rs.html. Accessed November 13, 1999.
66. Cutson TM, Sloane R, Schenkman M. Development of a clinical rating scale for persons with Parkinson's disease. J Am Geriatr Soc 1999;47:763-764.
67. Hempel AG, Wagner ML, Maaty MA, Sage JI. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in Parkinsonian patients with motor fluctuations. Ann Pharmacother 1998;32:878-883.
68. Hoerger TJ, Bala MV, Rawland C, Greer M, Chrischilles EA, Holoway RG. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998;14:541-557.
69. Hubble JP. Parkinson's disease and parkinsonian syndromes. Med Clin North Am 1999;83:525-536.
70. Rascol O, Blin O, Thalamas C, et al. ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 1999;45:736-741.
71. Montgomery EB, Lieberman A, Singh G, Fries JF. Patient education and health promotion can be effective in Parkinson's disease: A randomized controlled trial. Am J Med 1994;97:429-435.